Bonnie Bassler - Sanofi ADR Director

Director

Ms. Bonnie Bassler is Board Member of Sanofi SA. She graduated from University of California Davis with a degree in Biochemistry and obtained her Doctorate from John Hopkins University on Biochemistry. She is Member of the Narional Science Foundation and Board Member of American Association for the Advancement of Science. since 2014.
Tenure 10 years
Phone33 1 53 77 40 00
Webhttps://www.sanofi.com

Sanofi ADR Management Efficiency

The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 18.42 B in debt with debt to equity (D/E) ratio of 0.3, which may show that the company is not taking advantage of profits from borrowing. Sanofi ADR has a current ratio of 1.27, demonstrating that it may have difficulties to pay its financial commitments when the payables are due. Debt can assist Sanofi ADR until it has trouble settling it off, either with new capital or with free cash flow. So, Sanofi ADR's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sanofi ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sanofi to invest in growth at high rates of return. When we think about Sanofi ADR's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Marc TessierLavigneRegeneron Pharmaceuticals
58
Donald DenkhausCatalyst Pharmaceuticals
72
George SingRegeneron Pharmaceuticals
68
Fred MiddletonChimerix
67
James KernTscan Therapeutics
49
Philip CoelhoCatalyst Pharmaceuticals
74
Joseph SchepersChimerix
58
David TierneyCatalyst Pharmaceuticals
54
Richard GoodrichChart Industries
73
Lisa RicciardiChimerix
57
Admiral GiambastianiTscan Therapeutics
N/A
Nancy HawthorneTscan Therapeutics
66
David SagehornChart Industries
57
Martha DemskiChimerix
65
Michael MolininiChart Industries
69
Timothy WollaegerChimerix
68
Ronald RenaudChimerix
48
Catherine GillissChimerix
66
Christine PoonRegeneron Pharmaceuticals
65
Thomas WilliamsChart Industries
59
Anthony ColesRegeneron Pharmaceuticals
57
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 95442 people. Sanofi ADR (SNY) is traded on NASDAQ Exchange in USA. It is located in 46, avenue de la Grande Armée,, Paris, France, 75017 and employs 86,088 people. Sanofi ADR is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Sanofi ADR Leadership Team

Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee
Emmanuel Babeau, Independent Director
Roy Papatheodorou, Executive Counsel
Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team
Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee
Dieter Weinand, Executive Vice President Member of the Executive Board
Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team
Eva SchaeferJansen, Head Relations
Fabienne Lecorvaisier, Director
George Grofik, Vice President of Investor Relations
Karen Linehan, Executive VP of Legal Affairs and General Counsel
Klaus Pohle, Independent Director
John Reed, President - Global Research & Development, Member of the Executive Committee
Bernard Charles, Independent Director
Melanie Lee, Independent Director
Madeleine Roach, Executive Operations
Pierre Chancel, Senior Marketing
Christophe Babule, Director
Bonnie Bassler, Director
Thomas Suedhof, Independent Director
Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee
Laurent Attal, Director
JeanRene Fourtou, Independent Director
JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee
Josephine Fubara, Chief Care
Christian Mulliez, Director
Robert Castaigne, Independent Director
Laurent Gilhodes, Principal Accounting
Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team
Uwe Bicker, Independent Director
Josep Catlla, Head Communications
Claudie Haignere, Independent Director
Olivier Brandicourt, CEO, Director and Member of Strategy Committee
Paul Hudson, CEO Director
Bruno Mnard, Chief officer
Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team
Dante Beccaria, Global VP
Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee
William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee
Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team
David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe
Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team
Diane Souza, Independent Director
Carole Piwnica, Independent Director
Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team
Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee
Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team
Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team
DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee
Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team
Igor Landau, Director
Patrick Kron, Independent Director
Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee
Gerard Kemmel, Independent Director
SuetFern Lee, Independent Director
Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team
David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team
Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee
Suet Lee, Independent Director

Sanofi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Tools for Sanofi Stock

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets